{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:50:46Z","timestamp":1791337846312,"version":"4.3.1"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T00:00:00Z","timestamp":1435017600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1038\/nrneurol.2015.99","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T09:47:57Z","timestamp":1435052877000},"page":"401-413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Interactions of the histamine and hypocretin systems in CNS disorders"],"prefix":"10.1038","volume":"11","author":[{"given":"Ling","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Dauvilliers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome M.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,23]]},"reference":[{"key":"BFnrneurol201599_CR1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00005053-193003000-00001","volume":"71","author":"C von Economo","year":"1930","unstructured":"von Economo, C. Sleep as a problem of localization. J. Nerv. Ment. Dis. 71, 249\u2013259 (1930).","journal-title":"J. Nerv. Ment. Dis."},{"key":"BFnrneurol201599_CR2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","volume":"6","author":"C Peyron","year":"2000","unstructured":"Peyron, C. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991\u2013997 (2000).","journal-title":"Nat. Med."},{"key":"BFnrneurol201599_CR3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","volume":"27","author":"TC Thannickal","year":"2000","unstructured":"Thannickal, T. C. et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27, 469\u2013474 (2000).","journal-title":"Neuron"},{"key":"BFnrneurol201599_CR4","unstructured":"American Academy of Sleep Medicine. International Classification of Sleep Disorders: Diagnostic and Coding Manual 3rd edn (AASM, 2014)."},{"key":"BFnrneurol201599_CR5","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ana.23968","volume":"74","author":"J John","year":"2013","unstructured":"John, J. et al. Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. Ann. Neurol. 74, 786\u2013793 (2013).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201599_CR6","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ana.24019","volume":"74","author":"PO Valko","year":"2013","unstructured":"Valko, P. O. et al. Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann. Neurol. 74, 794\u2013804 (2013).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201599_CR7","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1152\/physrev.00043.2007","volume":"88","author":"HL Haas","year":"2008","unstructured":"Haas, H. L., Sergeeva, O. A. & Selbach, O. Histamine in the nervous system. Physiol. Rev. 88, 1183\u20131241 (2008).","journal-title":"Physiol. Rev."},{"key":"BFnrneurol201599_CR8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrn3526","volume":"14","author":"P Panula","year":"2013","unstructured":"Panula, P. & Nuutinen, S. The histaminergic network in the brain: basic organization and role in disease. Nat. Rev. Neurosci. 14, 472\u2013487 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"BFnrneurol201599_CR9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/ncomms2461","volume":"4","author":"AM Blouin","year":"2013","unstructured":"Blouin, A. M. et al. Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. Nat. Commun. 4, 1547 (2013).","journal-title":"Nat. Commun."},{"key":"BFnrneurol201599_CR10","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1523\/JNEUROSCI.22-13-05282.2002","volume":"22","author":"LI Kiyashchenko","year":"2002","unstructured":"Kiyashchenko, L. I. et al. Release of hypocretin (orexin) during waking and sleep states. J. Neurosci. 22, 5282\u20135286 (2002).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201599_CR11","doi-asserted-by":"crossref","first-page":"15455","DOI":"10.1523\/JNEUROSCI.4017-11.2011","volume":"31","author":"R McGregor","year":"2011","unstructured":"McGregor, R., Wu, M. F., Barber, G., Ramanathan, L. & Siegel, J. M. Highly specific role of hypocretin (orexin) neurons: differential activation as a function of diurnal phase, operant reinforcement versus operant avoidance and light level. J. Neurosci. 31, 15455\u201315467 (2011).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201599_CR12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.neuron.2005.04.035","volume":"46","author":"BY Mileykovskiy","year":"2005","unstructured":"Mileykovskiy, B. Y., Kiyashchenko, L. I. & Siegel, J. M. Behavioral correlates of activity in identified hypocretin\/orexin neurons. Neuron 46, 787\u2013798 (2005).","journal-title":"Neuron"},{"key":"BFnrneurol201599_CR13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0006-8993(02)02546-5","volume":"939","author":"S Trottier","year":"2002","unstructured":"Trottier, S. et al. Co-localization of histamine with GABA but not with galanin in the human tuberomamillary nucleus. Brain Res. 939, 52\u201364 (2002).","journal-title":"Brain Res."},{"key":"BFnrneurol201599_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cne.902630102","volume":"263","author":"H Ericson","year":"1987","unstructured":"Ericson, H., Watanabe, T. & Kohler, C. Morphological analysis of the tuberomammillary nucleus in the rat brain: delineation of subgroups with antibody against L-histidine decarboxylase as a marker. J. Comp. Neurol. 263, 1\u201324 (1987).","journal-title":"J. Comp. Neurol."},{"key":"BFnrneurol201599_CR15","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1523\/JNEUROSCI.18-12-04705.1998","volume":"18","author":"JE Sherin","year":"1998","unstructured":"Sherin, J. E., Elmquist, J. K., Torrealba, F. & Saper, C. B. Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J. Neurosci. 18, 4705\u20134721 (1998).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201599_CR16","doi-asserted-by":"crossref","first-page":"13062","DOI":"10.1523\/JNEUROSCI.2931-12.2012","volume":"32","author":"AY Zecharia","year":"2012","unstructured":"Zecharia, A. Y. et al. GABAergic inhibition of histaminergic neurons regulates active waking but not the sleep-wake switch or propofol-induced loss of consciousness. J. Neurosci. 32, 13062\u201313075 (2012).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201599_CR17","doi-asserted-by":"crossref","first-page":"R704","DOI":"10.1152\/ajpregu.00114.2014","volume":"307","author":"J John","year":"2014","unstructured":"John, J., Kodama, T. & Siegel, J. M. Caffeine promotes glutamate and histamine release in the posterior hypothalamus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 307, R704\u2013R710 (2014).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"BFnrneurol201599_CR18","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1016\/j.cub.2014.10.019","volume":"24","author":"X Yu","year":"2014","unstructured":"Yu, X. et al. Circadian factor BMAL1 in histaminergic neurons regulates sleep architecture. Curr. Biol. 24, 2838\u20132844 (2014).","journal-title":"Curr. Biol."},{"key":"BFnrneurol201599_CR19","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1002\/cne.22480","volume":"518","author":"DM Krolewski","year":"2010","unstructured":"Krolewski, D. M. et al. Expression patterns of corticotropin-releasing factor, arginine vasopressin, histidine decarboxylase, melanin-concentrating hormone, and orexin genes in the human hypothalamus. J. Comp. Neurol. 518, 4591\u20134611 (2010).","journal-title":"J. Comp. Neurol."},{"key":"BFnrneurol201599_CR20","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1210\/jc.2005-0296","volume":"90","author":"R Fronczek","year":"2005","unstructured":"Fronczek, R., Lammers, G. J., Balesar, R., Unmehopa, U. A. & Swaab, D. F. The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader\u2013Willi syndrome. J. Clin. Endocrinol. Metab. 90, 5466\u20135470 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneurol201599_CR21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","volume":"92","author":"T Sakurai","year":"1998","unstructured":"Sakurai, T. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573\u2013585 (1998).","journal-title":"Cell"},{"key":"BFnrneurol201599_CR22","doi-asserted-by":"crossref","first-page":"RC168","DOI":"10.1523\/JNEUROSCI.21-19-j0003.2001","volume":"21","author":"TC Chou","year":"2001","unstructured":"Chou, T. C. et al. Orexin (hypocretin) neurons contain dynorphin. J. Neurosci. 21, RC168 (2001).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201599_CR23","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1212\/01.WNL.0000168173.71940.ab","volume":"65","author":"A Crocker","year":"2005","unstructured":"Crocker, A. et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 65, 1184\u20131188 (2005).","journal-title":"Neurology"},{"key":"BFnrneurol201599_CR24","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0306-4522(03)00238-0","volume":"119","author":"F Torrealba","year":"2003","unstructured":"Torrealba, F., Yanagisawa, M. & Saper, C. B. Colocalization of orexin a and glutamate immunoreactivity in axon terminals in the tuberomammillary nucleus in rats. Neuroscience 119, 1033\u20131044 (2003).","journal-title":"Neuroscience"},{"key":"BFnrneurol201599_CR25","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1046\/j.1471-4159.2002.01141.x","volume":"82","author":"IM Reti","year":"2002","unstructured":"Reti, I. M., Reddy, R., Worley, P. F. & Baraban, J. M. Selective expression of Narp, a secreted neuronal pentraxin, in orexin neurons. J. Neurochem. 82, 1561\u20131565 (2002).","journal-title":"J. Neurochem."},{"key":"BFnrneurol201599_CR26","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1212\/01.wnl.0000175219.01544.c8","volume":"65","author":"AM Blouin","year":"2005","unstructured":"Blouin, A. M. et al. Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology 65, 1189\u20131192 (2005).","journal-title":"Neurology"},{"key":"BFnrneurol201599_CR27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neuron.2010.09.006","volume":"68","author":"L Appelbaum","year":"2010","unstructured":"Appelbaum, L. et al. Circadian and homeostatic regulation of structural synaptic plasticity in hypocretin neurons. Neuron 68, 87\u201398 (2010).","journal-title":"Neuron"},{"key":"BFnrneurol201599_CR28","doi-asserted-by":"crossref","first-page":"20090","DOI":"10.1073\/pnas.0710131104","volume":"104","author":"S Maret","year":"2007","unstructured":"Maret, S. et al. Homer1a is a core brain molecular correlate of sleep loss. Proc. Natl Acad. Sci. USA 104, 20090\u201320095 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol201599_CR29","doi-asserted-by":"crossref","first-page":"E1648","DOI":"10.1073\/pnas.1315542111","volume":"111","author":"JW Muschamp","year":"2014","unstructured":"Muschamp, J. W. et al. Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proc. Natl Acad. Sci. USA 111, E1648\u2013E1655 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol201599_CR30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1389-9457(02)00062-X","volume":"3","author":"A Vourdas","year":"2002","unstructured":"Vourdas, A. et al. Narcolepsy and psychopathology: is there an association? Sleep Med. 3, 353\u2013360 (2002).","journal-title":"Sleep Med."},{"key":"BFnrneurol201599_CR31","first-page":"1012","volume":"20","author":"E Mignot","year":"1997","unstructured":"Mignot, E., Hayduk, R., Black, J., Grumet, F. C. & Guilleminault, C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 20, 1012\u20131020 (1997).","journal-title":"Sleep"},{"key":"BFnrneurol201599_CR32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature13186","volume":"508","author":"SW Oh","year":"2014","unstructured":"Oh, S. W. et al. A mesoscale connectome of the mouse brain. Nature 508, 207\u2013214 (2014).","journal-title":"Nature"},{"key":"BFnrneurol201599_CR33","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","volume":"18","author":"C Peyron","year":"1998","unstructured":"Peyron, C. et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996\u201310015 (1998).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201599_CR34","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1006\/bbrc.2001.6318","volume":"290","author":"A Yamanaka","year":"2002","unstructured":"Yamanaka, A. et al. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem. Biophys. Res. Commun. 290, 1237\u20131245 (2002).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrneurol201599_CR35","doi-asserted-by":"crossref","first-page":"9965","DOI":"10.1073\/pnas.181330998","volume":"98","author":"ZL Huang","year":"2001","unstructured":"Huang, Z. L. et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc. Natl Acad. Sci. USA 98, 9965\u20139970 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol201599_CR36","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","volume":"98","author":"RM Chemelli","year":"1999","unstructured":"Chemelli, R. M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437\u2013451 (1999).","journal-title":"Cell"},{"key":"BFnrneurol201599_CR37","doi-asserted-by":"crossref","first-page":"9273","DOI":"10.1523\/JNEUROSCI.21-23-09273.2001","volume":"21","author":"KS Eriksson","year":"2001","unstructured":"Eriksson, K. S., Sergeeva, O., Brown, R. E. & Haas, H. L. Orexin\/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J. Neurosci. 21, 9273\u20139279 (2001).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201599_CR38","doi-asserted-by":"crossref","first-page":"12437","DOI":"10.1523\/JNEUROSCI.0706-12.2012","volume":"32","author":"C Schone","year":"2012","unstructured":"Schone, C. et al. Optogenetic probing of fast glutamatergic transmission from hypocretin\/orexin to histamine neurons in situ. J. Neurosci. 32, 12437\u201312443 (2012).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201599_CR39","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1096\/fj.11-188268","volume":"25","author":"M Sundvik","year":"2011","unstructured":"Sundvik, M. et al. The histaminergic system regulates wakefulness and orexin\/hypocretin neuron development via histamine receptor H1 in zebrafish. FASEB J. 25, 4338\u20134347 (2011).","journal-title":"FASEB J."},{"key":"BFnrneurol201599_CR40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tins.2014.01.001","volume":"37","author":"P Panula","year":"2014","unstructured":"Panula, P., Sundvik, M. & Karlstedt, K. Developmental roles of brain histamine. Trends Neurosci. 37, 159\u2013168 (2014).","journal-title":"Trends Neurosci."},{"key":"BFnrneurol201599_CR41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/apha.12432","volume":"213","author":"M Sundvik","year":"2015","unstructured":"Sundvik, M. & Panula, P. Interactions of the orexin\/hypocretin neurones and the histaminergic system. Acta Physiol. (Oxf.) 213, 321\u2013333 (2015).","journal-title":"Acta Physiol. (Oxf.)"},{"key":"BFnrneurol201599_CR42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuron.2005.03.010","volume":"46","author":"T Sakurai","year":"2005","unstructured":"Sakurai, T. et al. Input of orexin\/hypocretin neurons revealed by a genetically encoded tracer in mice. Neuron 46, 297\u2013308 (2005).","journal-title":"Neuron"},{"key":"BFnrneurol201599_CR43","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/cne.20859","volume":"494","author":"K Yoshida","year":"2006","unstructured":"Yoshida, K., McCormack, S., Espana, R. A., Crocker, A. & Scammell, T. E. Afferents to the orexin neurons of the rat brain. J. Comp. Neurol. 494, 845\u2013861 (2006).","journal-title":"J. Comp. Neurol."},{"key":"BFnrneurol201599_CR44","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0006-8993(99)01648-0","volume":"840","author":"TL Steininger","year":"1999","unstructured":"Steininger, T. L., Alam, M. N., Gong, H., Szymusiak, R. & McGinty, D. Sleep\u2013waking discharge of neurons in the posterior lateral hypothalamus of the albino rat. Brain Res. 840, 138\u2013147 (1999).","journal-title":"Brain Res."},{"key":"BFnrneurol201599_CR45","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/smrv.2000.0116","volume":"4","author":"JS Lin","year":"2000","unstructured":"Lin, J. S. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med. Rev. 4, 471\u2013503 (2000).","journal-title":"Sleep Med. Rev."},{"key":"BFnrneurol201599_CR46","doi-asserted-by":"crossref","first-page":"7695","DOI":"10.1523\/JNEUROSCI.22-17-07695.2002","volume":"22","author":"R Parmentier","year":"2002","unstructured":"Parmentier, R. et al. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J. Neurosci. 22, 7695\u20137711 (2002).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201599_CR47","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1073\/pnas.0600451103","volume":"103","author":"ZL Huang","year":"2006","unstructured":"Huang, Z. L. et al. Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice. Proc. Natl Acad. Sci. USA 103, 4687\u20134692 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol201599_CR48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.resp.2006.01.017","volume":"154","author":"T Ishiguro","year":"2006","unstructured":"Ishiguro, T. et al. Impaired ventilation and metabolism response to hypoxia in histamine H1 receptor-knockout mice. Respir. Physiol. Neurobiol. 154, 331\u2013341 (2006).","journal-title":"Respir. Physiol. Neurobiol."},{"key":"BFnrneurol201599_CR49","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/npp.2012.266","volume":"38","author":"E Gondard","year":"2013","unstructured":"Gondard, E. et al. Enhanced histaminergic neurotransmission and sleep-wake alterations, a study in histamine H3-receptor knock-out mice. Neuropsychopharmacology 38, 1015\u20131031 (2013).","journal-title":"Neuropsychopharmacology"},{"key":"BFnrneurol201599_CR50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0304-3940(01)02270-4","volume":"313","author":"S Nishino","year":"2001","unstructured":"Nishino, S. et al. Decreased brain histamine content in hypocretin\/orexin receptor-2 mutated narcoleptic dogs. Neurosci. Lett. 313, 125\u2013128 (2001).","journal-title":"Neurosci. Lett."},{"key":"BFnrneurol201599_CR51","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1046\/j.0953-816x.2001.01725.x","volume":"14","author":"Y Yoshida","year":"2001","unstructured":"Yoshida, Y. et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep\u2013wake activities. Eur. J. Neurosci. 14, 1075\u20131081 (2001).","journal-title":"Eur. J. Neurosci."},{"key":"BFnrneurol201599_CR52","doi-asserted-by":"crossref","first-page":"14423","DOI":"10.1523\/JNEUROSCI.2604-09.2009","volume":"29","author":"C Anaclet","year":"2009","unstructured":"Anaclet, C. et al. Orexin\/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models. J. Neurosci. 29, 14423\u201314438 (2009).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201599_CR53","doi-asserted-by":"crossref","first-page":"713","DOI":"10.5665\/sleep.1838","volume":"35","author":"L Shan","year":"2012","unstructured":"Shan, L. et al. Diurnal fluctuation in histidine decarboxylase expression, the rate limiting enzyme for histamine production, and its disorder in neurodegenerative diseases. Sleep 35, 713\u2013715 (2012).","journal-title":"Sleep"},{"key":"BFnrneurol201599_CR54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2869.2011.00957.x","volume":"21","author":"JM Zeitzer","year":"2012","unstructured":"Zeitzer, J. M. et al. Time-course of cerebrospinal fluid histamine in the wake-consolidated squirrel monkey. J. Sleep Res. 21, 189\u2013194 (2012).","journal-title":"J. Sleep Res."},{"key":"BFnrneurol201599_CR55","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/0091-3057(94)90254-2","volume":"49","author":"T Kiviranta","year":"1994","unstructured":"Kiviranta, T., Tuomisto, L. & Airaksinen, E. M. Diurnal and age-related changes in cerebrospinal fluid tele-methylhistamine levels during infancy and childhood. Pharmacol. Biochem. Behav. 49, 997\u20131000 (1994).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"BFnrneurol201599_CR56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0006-3223(02)01740-7","volume":"54","author":"RM Salomon","year":"2003","unstructured":"Salomon, R. M. et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol. Psychiatry 54, 96\u2013104 (2003).","journal-title":"Biol. Psychiatry"},{"key":"BFnrneurol201599_CR57","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/S0196-9781(02)00251-6","volume":"23","author":"L Lin","year":"2002","unstructured":"Lin, L. et al. Measurement of hypocretin\/orexin content in the mouse brain using an enzyme immunoassay: the effect of circadian time, age and genetic background. Peptides 23, 2203\u20132211 (2002).","journal-title":"Peptides"},{"key":"BFnrneurol201599_CR58","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nrneurol.2014.97","volume":"10","author":"Y Dauvilliers","year":"2014","unstructured":"Dauvilliers, Y., Siegel, J. M., Lopez, R., Torontali, Z. A. & Peever, J. H. Cataplexy\u2014clinical aspects, pathophysiology and management strategy. Nat. Rev. Neurol. 10, 386\u2013395 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"BFnrneurol201599_CR59","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(07)60237-2","volume":"369","author":"Y Dauvilliers","year":"2007","unstructured":"Dauvilliers, Y., Arnulf, I. & Mignot, E. Narcolepsy with cataplexy. Lancet 369, 499\u2013511 (2007).","journal-title":"Lancet"},{"key":"BFnrneurol201599_CR60","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1212\/WNL.57.12.2253","volume":"57","author":"B Ripley","year":"2001","unstructured":"Ripley, B. et al. CSF hypocretin\/orexin levels in narcolepsy and other neurological conditions. Neurology 57, 2253\u20132258 (2001).","journal-title":"Neurology"},{"key":"BFnrneurol201599_CR61","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","volume":"59","author":"E Mignot","year":"2002","unstructured":"Mignot, E. et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 59, 1553\u20131562 (2002).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol201599_CR62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","volume":"355","author":"S Nishino","year":"2000","unstructured":"Nishino, S., Ripley, B., Overeem, S., Lammers, G. J. & Mignot, E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355, 39\u201340 (2000).","journal-title":"Lancet"},{"key":"BFnrneurol201599_CR63","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/sleep\/32.8.993","volume":"32","author":"TC Thannickal","year":"2009","unstructured":"Thannickal, T. C., Nienhuis, R. & Siegel, J. M. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 32, 993\u2013998 (2009).","journal-title":"Sleep"},{"key":"BFnrneurol201599_CR64","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5665\/sleep\/32.1.111","volume":"32","author":"TE Scammell","year":"2009","unstructured":"Scammell, T. E., Willie, J. T., Guilleminault, C., Siegel, J. M. & International Working Group on Rodent Models of, N. A consensus definition of cataplexy in mouse models of narcolepsy. Sleep 32, 111\u2013116 (2009).","journal-title":"Sleep"},{"key":"BFnrneurol201599_CR65","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/sleep\/32.2.175","volume":"32","author":"S Nishino","year":"2009","unstructured":"Nishino, S. et al. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep 32, 175\u2013180 (2009).","journal-title":"Sleep"},{"key":"BFnrneurol201599_CR66","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0306-4522(98)00600-9","volume":"91","author":"MF Wu","year":"1999","unstructured":"Wu, M. F. et al. Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience 91, 1389\u20131399 (1999).","journal-title":"Neuroscience"},{"key":"BFnrneurol201599_CR67","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1126\/science.1925546","volume":"252","author":"JM Siegel","year":"1991","unstructured":"Siegel, J. M. et al. Neuronal activity in narcolepsy: identification of cataplexy-related cells in the medial medulla. Science 252, 1315\u20131318 (1991).","journal-title":"Science"},{"key":"BFnrneurol201599_CR68","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0896-6273(04)00247-8","volume":"42","author":"J John","year":"2004","unstructured":"John, J., Wu, M. F., Boehmer, L. N. & Siegel, J. M. Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. Neuron 42, 619\u2013634 (2004).","journal-title":"Neuron"},{"key":"BFnrneurol201599_CR69","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/B978-1-4160-6645-3.00008-6","volume-title":"Principles and Practice of Sleep Medicine","author":"JM Siegel","year":"2011","unstructured":"Siegel, J. M. in Principles and Practice of Sleep Medicine 5th edn (eds Kryger, M. H. et al.) 92\u2013111 (Elsevier Saunders, 2011)."},{"key":"BFnrneurol201599_CR70","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1523\/JNEUROSCI.0073-14.2014","volume":"34","author":"S Tabuchi","year":"2014","unstructured":"Tabuchi, S. et al. Conditional ablation of orexin\/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J. Neurosci. 34, 6495\u20136509 (2014).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201599_CR71","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.5665\/sleep.2114","volume":"35","author":"Y Dauvilliers","year":"2012","unstructured":"Dauvilliers, Y. et al. Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions. Sleep 35, 1359\u20131366 (2012).","journal-title":"Sleep"},{"key":"BFnrneurol201599_CR72","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/brain\/awq086","volume":"133","author":"A Fontana","year":"2010","unstructured":"Fontana, A. et al. Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss? Brain 133, 1300\u20131311 (2010).","journal-title":"Brain"},{"key":"BFnrneurol201599_CR73","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/sleep\/32.8.979","volume":"32","author":"A Aran","year":"2009","unstructured":"Aran, A. et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32, 979\u2013983 (2009).","journal-title":"Sleep"},{"key":"BFnrneurol201599_CR74","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/brain\/awt187","volume":"136","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers, Y. et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 136, 2486\u20132496 (2013).","journal-title":"Brain"},{"key":"BFnrneurol201599_CR75","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1474-4422(14)70075-4","volume":"13","author":"M Partinen","year":"2014","unstructured":"Partinen, M. et al. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol. 13, 600\u2013613 (2014).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol201599_CR76","doi-asserted-by":"crossref","first-page":"E3735","DOI":"10.1073\/pnas.1412189111","volume":"111","author":"P Bergman","year":"2014","unstructured":"Bergman, P. et al. Narcolepsy patients have antibodies that stain distinct cell populations in rat brain and influence sleep patterns. Proc. Natl Acad. Sci. USA 111, E3735\u2013E3744 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol201599_CR77","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1172\/JCI41366","volume":"120","author":"V Cvetkovic-Lopes","year":"2010","unstructured":"Cvetkovic-Lopes, V. et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J. Clin. Invest. 120, 713\u2013719 (2010).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol201599_CR78","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1471-4906(03)00233-3","volume":"24","author":"R Pedotti","year":"2003","unstructured":"Pedotti, R., De Voss, J. J., Steinman, L. & Galli, S. J. Involvement of both 'allergic' and 'autoimmune' mechanisms in EAE, MS and other autoimmune diseases. Trends Immunol. 24, 479\u2013484 (2003).","journal-title":"Trends Immunol."},{"key":"BFnrneurol201599_CR79","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1212\/01.wnl.0000198507.13597.45","volume":"66","author":"A Alonso","year":"2006","unstructured":"Alonso, A., Jick, S. S. & Hernan, M. A. Allergy, histamine 1 receptor blockers, and the risk of multiple sclerosis. Neurology 66, 572\u2013575 (2006).","journal-title":"Neurology"},{"key":"BFnrneurol201599_CR80","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm0502-500","volume":"8","author":"C Lock","year":"2002","unstructured":"Lock, C. et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8, 500\u2013508 (2002).","journal-title":"Nat. Med."},{"key":"BFnrneurol201599_CR81","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fnagi.2014.00119","volume":"6","author":"YA Dauvilliers","year":"2014","unstructured":"Dauvilliers, Y. A., Lehmann, S., Jaussent, I. & Gabelle, A. Hypocretin and brain beta-amyloid peptide interactions in cognitive disorders and narcolepsy. Front. Aging Neurosci. 6, 119 (2014).","journal-title":"Front. Aging Neurosci."},{"key":"BFnrneurol201599_CR82","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1084\/jem.20030320","volume":"197","author":"L Steinman","year":"2003","unstructured":"Steinman, L. Optic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year. J. Exp. Med. 197, 1065\u20131071 (2003).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol201599_CR83","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/ni0901-762","volume":"2","author":"L Steinman","year":"2001","unstructured":"Steinman, L. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2, 762\u2013764 (2001).","journal-title":"Nat. Immunol."},{"key":"BFnrneurol201599_CR84","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0952-7915(02)00395-3","volume":"14","author":"M Jutel","year":"2002","unstructured":"Jutel, M., Watanabe, T., Akdis, M., Blaser, K. & Akdis, C. A. Immune regulation by histamine. Curr. Opin. Immunol. 14, 735\u2013740 (2002).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrneurol201599_CR85","doi-asserted-by":"crossref","first-page":"10146","DOI":"10.1073\/pnas.0702291104","volume":"104","author":"C Teuscher","year":"2007","unstructured":"Teuscher, C. et al. Central histamine H3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS. Proc. Natl Acad. Sci. USA 104, 10146\u201310151 (2007).","journal-title":"Proc. Natl Acad. Sci."},{"key":"BFnrneurol201599_CR86","first-page":"237","volume":"14","author":"PJ Magistretti","year":"1988","unstructured":"Magistretti, P. J. Regulation of glycogenolysis by neurotransmitters in the central nervous system. Diabete. Metab. 14, 237\u2013246 (1988).","journal-title":"Diabete. Metab."},{"key":"BFnrneurol201599_CR87","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.sleep.2014.02.005","volume":"15","author":"MS Heier","year":"2014","unstructured":"Heier, M. S., Skinningsrud, A., Paus, E. & Gautvik, K. M. Increased cerebrospinal fluid levels of nerve cell biomarkers in narcolepsy with cataplexy. Sleep Med. 15, 614\u2013618 (2014).","journal-title":"Sleep Med."},{"key":"BFnrneurol201599_CR88","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/35096564","volume":"413","author":"M Jutel","year":"2001","unstructured":"Jutel, M. et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 413, 420\u2013425 (2001).","journal-title":"Nature"},{"key":"BFnrneurol201599_CR89","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0166-2236(96)81863-7","volume":"19","author":"R Silver","year":"1996","unstructured":"Silver, R., Silverman, A. J., Vitkovi\u0107, L. & Lederhendler, I. I. Mast cells in the brain: evidence and functional significance. Trends Neurosci. 19, 25\u201331 (1996).","journal-title":"Trends Neurosci."},{"key":"BFnrneurol201599_CR90","doi-asserted-by":"crossref","first-page":"e78434","DOI":"10.1371\/journal.pone.0078434","volume":"8","author":"S Chikahisa","year":"2013","unstructured":"Chikahisa, S. et al. Histamine from brain resident MAST cells promotes wakefulness and modulates behavioral states. PLoS ONE 8, e78434 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrneurol201599_CR91","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fncel.2014.00120","volume":"8","author":"SM Rocha","year":"2014","unstructured":"Rocha, S. M., Pires, J., Esteves, M., Graca, B. & Bernardino, L. Histamine: a new immunomodulatory player in the neuron-glia crosstalk. Front. Cell. Neurosci. 8, 120 (2014).","journal-title":"Front. Cell. Neurosci."},{"key":"BFnrneurol201599_CR92","doi-asserted-by":"crossref","first-page":"12557","DOI":"10.1523\/JNEUROSCI.0595-13.2013","volume":"33","author":"K Obukuro","year":"2013","unstructured":"Obukuro, K. et al. Nitric oxide mediates selective degeneration of hypothalamic orexin neurons through dysfunction of protein disulfide isomerase. J. Neurosci. 33, 12557\u201312568 (2013).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201599_CR93","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0301-0082(00)00032-0","volume":"64","author":"TW Stone","year":"2001","unstructured":"Stone, T. W. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog. Neurobiol. 64, 185\u2013218 (2001).","journal-title":"Prog. Neurobiol."},{"key":"BFnrneurol201599_CR94","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.nbd.2003.09.003","volume":"15","author":"H Katsuki","year":"2004","unstructured":"Katsuki, H. & Akaike, A. Excitotoxic degeneration of hypothalamic orexin neurons in slice culture. Neurobiol. Dis. 15, 61\u201369 (2004).","journal-title":"Neurobiol. Dis."},{"key":"BFnrneurol201599_CR95","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tins.2014.12.008","volume":"38","author":"L Shan","year":"2015","unstructured":"Shan, L., Bao, A. M. & Swaab, D. F. The human histaminergic system in neuropsychiatric disorders. Trends Neurosci. 38, 167\u2013177 (2015).","journal-title":"Trends Neurosci."},{"key":"BFnrneurol201599_CR96","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1006\/exnr.2000.7362","volume":"163","author":"OV Anichtchik","year":"2000","unstructured":"Anichtchik, O. V., Rinne, J. O., Kalimo, H. & Panula, P. An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp. Neurol. 163, 20\u201330 (2000).","journal-title":"Exp. Neurol."},{"key":"BFnrneurol201599_CR97","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1046\/j.1471-4159.2002.00871.x","volume":"81","author":"JO Rinne","year":"2002","unstructured":"Rinne, J. O. et al. Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy. J. Neurochem. 81, 954\u2013960 (2002).","journal-title":"J. Neurochem."},{"key":"BFnrneurol201599_CR98","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.neuropharm.2007.08.014","volume":"53","author":"CQ Liu","year":"2007","unstructured":"Liu, C. Q., Chen, Z., Liu, F. X., Hu, D. N. & Luo, J. H. Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats. Neuropharmacology 53, 832\u2013841 (2007).","journal-title":"Neuropharmacology"},{"key":"BFnrneurol201599_CR99","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pbb.2008.03.010","volume":"90","author":"CQ Liu","year":"2008","unstructured":"Liu, C. Q., Hu, D. N., Liu, F. X., Chen, Z. & Luo, J. H. Apomorphine-induced turning behavior in 6-hydroxydopamine lesioned rats is increased by histidine and decreased by histidine decarboxylase, histamine H1 and H2 receptor antagonists, and an H3 receptor agonist. Pharmacol. Biochem. Behav. 90, 325\u2013330 (2008).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"BFnrneurol201599_CR100","doi-asserted-by":"crossref","first-page":"207178","DOI":"10.1155\/2013\/207178","volume":"2013","author":"PA Defina","year":"2013","unstructured":"Defina, P. A., Moser, R. S., Glenn, M., Lichtenstein, J. D. & Fellus, J. Alzheimer's disease clinical and research update for health care practitioners. J. Aging Res. 2013, 207178 (2013).","journal-title":"J. Aging Res."},{"key":"BFnrneurol201599_CR101","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0531-5565(00)00191-1","volume":"35","author":"EJ Van Someren","year":"2000","unstructured":"Van Someren, E. J. Circadian and sleep disturbances in the elderly. Exp. Gerontol. 35, 1229\u20131237 (2000).","journal-title":"Exp. Gerontol."},{"key":"BFnrneurol201599_CR102","first-page":"108","volume":"6","author":"A Bianchetti","year":"1995","unstructured":"Bianchetti, A. et al. Predictors of mortality and institutionalization in Alzheimer disease patients 1 year after discharge from an Alzheimer dementia unit. Dementia 6, 108\u2013112 (1995).","journal-title":"Dementia"},{"key":"BFnrneurol201599_CR103","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000116984","volume":"33","author":"H Braak","year":"1993","unstructured":"Braak, H., Braak, E. & Bohl, J. Staging of Alzheimer-related cortical destruction. Eur. Neurol. 33, 403\u2013408 (1993).","journal-title":"Eur. Neurol."},{"key":"BFnrneurol201599_CR104","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.exger.2012.08.002","volume":"48","author":"L Shan","year":"2013","unstructured":"Shan, L., Swaab, D. F. & Bao, A. M. Neuronal histaminergic system in aging and age-related neurodegenerative disorders. Exp. Gerontol. 48, 603\u2013607 (2013).","journal-title":"Exp. Gerontol."},{"key":"BFnrneurol201599_CR105","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jamaneurol.2014.2510","volume":"71","author":"C Liguori","year":"2014","unstructured":"Liguori, C. et al. Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol. 71, 1498\u20131505 (2014).","journal-title":"JAMA Neurol."},{"key":"BFnrneurol201599_CR106","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1126\/science.1180962","volume":"326","author":"JE Kang","year":"2009","unstructured":"Kang, J. E. et al. Amyloid-\u03b2 dynamics are regulated by orexin and the sleep-wake cycle. Science 326, 1005\u20131007 (2009).","journal-title":"Science"},{"key":"BFnrneurol201599_CR107","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.neurobiolaging.2010.12.008","volume":"33","author":"TE Scammell","year":"2012","unstructured":"Scammell, T. E., Matheson, J. K., Honda, M., Thannickal, T. C. & Siegel, J. M. Coexistence of narcolepsy and Alzheimer's disease. Neurobiol. Aging 33, 1318\u20131319 (2012).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol201599_CR108","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.neurobiolaging.2011.03.014","volume":"33","author":"R Fronczek","year":"2012","unstructured":"Fronczek, R. et al. Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol. Aging 33, 1642\u20131650 (2012).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol201599_CR109","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0306-4522(91)90070-5","volume":"44","author":"MS Airaksinen","year":"1991","unstructured":"Airaksinen, M. S. et al. Histamine neurons in human hypothalamus: anatomy in normal and Alzheimer diseased brains. Neuroscience 44, 465\u2013481 (1991).","journal-title":"Neuroscience"},{"key":"BFnrneurol201599_CR110","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.neurobiolaging.2011.12.026","volume":"33","author":"L Shan","year":"2012","unstructured":"Shan, L., Bossers, K., Unmehopa, U., Bao, A. M. & Swaab, D. F. Alterations in the histaminergic system in Alzheimer's disease: a postmortem study. Neurobiol. Aging 33, 2585\u20132598 (2012).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol201599_CR111","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3233\/JAD-2010-100381","volume":"22","author":"M Motawaj","year":"2010","unstructured":"Motawaj, M., Peoc'h, K., Callebert, J. & Arrang, J. M. CSF levels of the histamine metabolite tele-methylhistamine are only slightly decreased in Alzheimer's disease. J. Alzheimers Dis. 22, 861\u2013871 (2010).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrneurol201599_CR112","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/1531-8249(199901)45:1<82::AID-ART14>3.0.CO;2-T","volume":"45","author":"WJ Hoogendijk","year":"1999","unstructured":"Hoogendijk, W. J. et al. Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann. Neurol. 45, 82\u201391 (1999).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201599_CR113","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1523\/JNEUROSCI.4265-05.2006","volume":"26","author":"P Szot","year":"2006","unstructured":"Szot, P. et al. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J. Neurosci. 26, 467\u2013478 (2006).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201599_CR114","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.tips.2011.01.003","volume":"32","author":"MB Passani","year":"2011","unstructured":"Passani, M. B. & Blandina, P. Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol. Sci. 32, 242\u2013249 (2011).","journal-title":"Trends Pharmacol. Sci."},{"key":"BFnrneurol201599_CR115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/156720512800492530","volume":"9","author":"M Egan","year":"2012","unstructured":"Egan, M. et al. Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD. Curr. Alzheimer Res. 9, 481\u2013490 (2012).","journal-title":"Curr. Alzheimer Res."},{"key":"BFnrneurol201599_CR116","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3233\/JAD-140291","volume":"42","author":"GM Haig","year":"2014","unstructured":"Haig, G. M. et al. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia. J. Alzheimers Dis. 42, 959\u2013971 (2014).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrneurol201599_CR117","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1567205010666131212110148","volume":"11","author":"RA Grove","year":"2014","unstructured":"Grove, R. A. et al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. Curr. Alzheimer Res. 11, 47\u201358 (2014).","journal-title":"Curr. Alzheimer Res."},{"key":"BFnrneurol201599_CR118","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tins.2007.03.009","volume":"30","author":"D Sulzer","year":"2007","unstructured":"Sulzer, D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 30, 244\u2013250 (2007).","journal-title":"Trends Neurosci."},{"key":"BFnrneurol201599_CR119","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol201599_CR120","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ncpneuro0775","volume":"4","author":"VC De Cock","year":"2008","unstructured":"De Cock, V. C., Vidailhet, M. & Arnulf, I. Sleep disturbances in patients with parkinsonism. Nat. Clin. Pract. Neurol. 4, 254\u2013266 (2008).","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"BFnrneurol201599_CR121","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.287.4.455","volume":"287","author":"DE Hobson","year":"2002","unstructured":"Hobson, D. E. et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 287, 455\u2013463 (2002).","journal-title":"JAMA"},{"key":"BFnrneurol201599_CR122","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1212\/01.wnl.0000183056.89590.0d","volume":"65","author":"RD Abbott","year":"2005","unstructured":"Abbott, R. D. et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 65, 1442\u20131446 (2005).","journal-title":"Neurology"},{"key":"BFnrneurol201599_CR123","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.smrv.2005.01.001","volume":"9","author":"I Arnulf","year":"2005","unstructured":"Arnulf, I. Excessive daytime sleepiness in parkinsonism. Sleep Med. Rev. 9, 185\u2013200 (2005).","journal-title":"Sleep Med. Rev."},{"key":"BFnrneurol201599_CR124","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1212\/WNL.58.7.1019","volume":"58","author":"I Arnulf","year":"2002","unstructured":"Arnulf, I. et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 58, 1019\u20131024 (2002).","journal-title":"Neurology"},{"key":"BFnrneurol201599_CR125","doi-asserted-by":"crossref","first-page":"e107278","DOI":"10.1371\/journal.pone.0107278","volume":"9","author":"V Cochen De Cock","year":"2014","unstructured":"Cochen De Cock, V. et al. Daytime sleepiness in Parkinson's disease: a reappraisal. PLoS ONE 9, e107278 (2014).","journal-title":"PLoS ONE"},{"key":"BFnrneurol201599_CR126","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1093\/brain\/awm221","volume":"131","author":"TC Thannickal","year":"2008","unstructured":"Thannickal, T. C., Lai, Y. Y. & Siegel, J. M. Hypocretin (orexin) and melanin concentrating hormone loss and the symptoms of Parkinson's disease. Brain 131, e87 (2008).","journal-title":"Brain"},{"key":"BFnrneurol201599_CR127","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/brain\/awm090","volume":"130","author":"R Fronczek","year":"2007","unstructured":"Fronczek, R. et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 130, 1577\u20131585 (2007).","journal-title":"Brain"},{"key":"BFnrneurol201599_CR128","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1212\/01.WNL.0000078194.53210.48","volume":"61","author":"X Drouot","year":"2003","unstructured":"Drouot, X. et al. Low levels of ventricular CSF orexin\/hypocretin in advanced PD. Neurology 61, 540\u2013543 (2003).","journal-title":"Neurology"},{"key":"BFnrneurol201599_CR129","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.58.3.498","volume":"58","author":"S Overeem","year":"2002","unstructured":"Overeem, S. et al. Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness. Neurology 58, 498\u2013499 (2002).","journal-title":"Neurology"},{"key":"BFnrneurol201599_CR130","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/brain\/awp263","volume":"132","author":"Y Compta","year":"2009","unstructured":"Compta, Y. et al. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain 132, 3308\u20133317 (2009).","journal-title":"Brain"},{"key":"BFnrneurol201599_CR131","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.neurobiolaging.2011.01.004","volume":"33","author":"L Shan","year":"2012","unstructured":"Shan, L. et al. Neuronal histamine production remains unaltered in Parkinson's disease despite the accumulation of Lewy bodies and Lewy neurites in the tuberomamillary nucleus. Neurobiol. Aging 33, 1343\u20131344 (2012).","journal-title":"Neurobiol. Aging"},{"key":"BFnrneurol201599_CR132","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1212\/WNL.46.6.1693","volume":"46","author":"S Nakamura","year":"1996","unstructured":"Nakamura, S. et al. Large neurons in the tuberomammillary nucleus in patients with Parkinson's disease and multiple system atrophy. Neurology 46, 1693\u20131696 (1996).","journal-title":"Neurology"},{"key":"BFnrneurol201599_CR133","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(83)91613-6","volume":"1","author":"M Garbarg","year":"1983","unstructured":"Garbarg, M., Javoy-Agid, F., Schwartz, J. C. & Agid, Y. Brain histidine decarboxylase activity in Parkinson's disease. Lancet 1, 74\u201375 (1983).","journal-title":"Lancet"},{"key":"BFnrneurol201599_CR134","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF01986584","volume":"33","author":"GD Prell","year":"1991","unstructured":"Prell, G. D. & Green, J. P. Histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid. Agents Actions Suppl. 33, 343\u2013363 (1991).","journal-title":"Agents Actions Suppl."},{"key":"BFnrneurol201599_CR135","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/mds.21971","volume":"23","author":"W Phillips","year":"2008","unstructured":"Phillips, W., Shannon, K. M. & Barker, R. A. The current clinical management of Huntington's disease. Mov. Disord. 23, 1491\u20131504 (2008).","journal-title":"Mov. Disord."},{"key":"BFnrneurol201599_CR136","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","volume":"330","author":"B Kremer","year":"1994","unstructured":"Kremer, B. et al. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N. Engl. J. Med. 330, 1401\u20131406 (1994).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol201599_CR137","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1750-3639.2008.00135.x","volume":"18","author":"A Aziz","year":"2008","unstructured":"Aziz, A. et al. Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol. 18, 474\u2013483 (2008).","journal-title":"Brain Pathol."},{"key":"BFnrneurol201599_CR138","first-page":"223","volume":"18","author":"NA Aziz","year":"2007","unstructured":"Aziz, N. A., Swaab, D. F., Pijl, H. & Roos, R. A. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev. Neurosci. 18, 223\u2013251 (2007).","journal-title":"Rev. Neurosci."},{"key":"BFnrneurol201599_CR139","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/hmg\/ddi004","volume":"14","author":"A Petersen","year":"2005","unstructured":"Petersen, A. et al. Orexin loss in Huntington's disease. Hum. Mol. Genet. 14, 39\u201347 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol201599_CR140","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493\u2013506 (1996).","journal-title":"Cell"},{"key":"BFnrneurol201599_CR141","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1007\/s00415-006-0146-7","volume":"253","author":"CR Baumann","year":"2006","unstructured":"Baumann, C. R., Hersberger, M. & Bassetti, C. L. Hypocretin-1 (orexin A) levels are normal in Huntington's disease. J. Neurol. 253, 1232\u20131233 (2006).","journal-title":"J. Neurol."},{"key":"BFnrneurol201599_CR142","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1750-3639.2010.00465.x","volume":"21","author":"DJ van Wamelen","year":"2011","unstructured":"van Wamelen, D. J. et al. Functional increase of brain histaminergic signaling in Huntington's disease. Brain Pathol. 21, 419\u2013427 (2011).","journal-title":"Brain Pathol."},{"key":"BFnrneurol201599_CR143","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.nbd.2011.02.006","volume":"42","author":"RH Williams","year":"2011","unstructured":"Williams, R. H., Morton, A. J. & Burdakov, D. Paradoxical function of orexin\/hypocretin circuits in a mouse model of Huntington's disease. Neurobiol. Dis. 42, 438\u2013445 (2011).","journal-title":"Neurobiol. Dis."},{"key":"BFnrneurol201599_CR144","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1523\/JNEUROSCI.3842-04.2005","volume":"25","author":"AJ Morton","year":"2005","unstructured":"Morton, A. J. et al. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J. Neurosci. 25, 157\u2013163 (2005).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201599_CR145","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.expneurol.2012.10.014","volume":"243","author":"AJ Morton","year":"2013","unstructured":"Morton, A. J. Circadian and sleep disorder in Huntington's disease. Exp. Neurol. 243, 34\u201344 (2013).","journal-title":"Exp. Neurol."},{"key":"BFnrneurol201599_CR146","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archneur.65.4.482","volume":"65","author":"I Arnulf","year":"2008","unstructured":"Arnulf, I. et al. Rapid eye movement sleep disturbances in Huntington disease. Arch. Neurol. 65, 482\u2013488 (2008).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol201599_CR147","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1056\/NEJMoa0907006","volume":"362","author":"AG Ercan-Sencicek","year":"2010","unstructured":"Ercan-Sencicek, A. G. et al. L-histidine decarboxylase and Tourette's syndrome. N. Engl. J. Med. 362, 1901\u20131908 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol201599_CR148","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/jmedgenet-2013-101637","volume":"50","author":"I Karagiannidis","year":"2013","unstructured":"Karagiannidis, I. et al. Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families. J. Med. Genet. 50, 760\u2013764 (2013).","journal-title":"J. Med. Genet."},{"key":"BFnrneurol201599_CR149","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neuron.2013.10.052","volume":"81","author":"L Castellan Baldan","year":"2014","unstructured":"Castellan Baldan, L. et al. Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice. Neuron 81, 77\u201390 (2014).","journal-title":"Neuron"},{"key":"BFnrneurol201599_CR150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pediatrneurol.2014.03.017","volume":"51","author":"D Ghosh","year":"2014","unstructured":"Ghosh, D. et al. Sleep disorders in children with Tourette syndrome. Pediatr. Neurol. 51, 31\u201335 (2014).","journal-title":"Pediatr. Neurol."},{"key":"BFnrneurol201599_CR151","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00415-011-6171-1","volume":"259","author":"A Hartmann","year":"2012","unstructured":"Hartmann, A., Worbe, Y. & Arnulf, I. Increasing histamine neurotransmission in Gilles de la Tourette syndrome. J. Neurol. 259, 375\u2013376 (2012).","journal-title":"J. Neurol."},{"key":"BFnrneurol201599_CR152","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2500\/aap.2009.30.3264","volume":"30","author":"P Lieberman","year":"2009","unstructured":"Lieberman, P. Histamine, antihistamines, and the central nervous system. Allergy Asthma Proc. 30, 482\u2013486 (2009).","journal-title":"Allergy Asthma Proc."},{"key":"BFnrneurol201599_CR153","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smrv.2012.08.001","volume":"17","author":"AD Krystal","year":"2013","unstructured":"Krystal, A. D., Richelson, E. & Roth, T. Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications. Sleep Med. Rev. 17, 263\u2013272 (2013).","journal-title":"Sleep Med. Rev."},{"key":"BFnrneurol201599_CR154","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/sleep\/30.11.1555","volume":"30","author":"T Roth","year":"2007","unstructured":"Roth, T. et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 30, 1555\u20131561 (2007).","journal-title":"Sleep"},{"key":"BFnrneurol201599_CR155","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","volume":"30","author":"JS Lin","year":"2008","unstructured":"Lin, J. S. et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin\u2212\/\u2212 mice and patients. Neurobiol. Dis. 30, 74\u201383 (2008).","journal-title":"Neurobiol. Dis."},{"key":"BFnrneurol201599_CR156","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/WNF.0b013e318246879d","volume":"35","author":"C Inocente","year":"2012","unstructured":"Inocente, C. et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin. Neuropharmacol. 35, 55\u201360 (2012).","journal-title":"Clin. Neuropharmacol."},{"key":"BFnrneurol201599_CR157","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","volume":"12","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers, Y. et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 12, 1068\u20131075 (2013).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol201599_CR158","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/sleep\/32.2.181","volume":"32","author":"T Kanbayashi","year":"2009","unstructured":"Kanbayashi, T. et al. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep 32, 181\u2013187 (2009).","journal-title":"Sleep"},{"key":"BFnrneurol201599_CR159","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jad.2012.09.008","volume":"146","author":"L Shan","year":"2013","unstructured":"Shan, L. Qi, X. R., Balesar, R., Swaab, D. F. & Bao, A. M. Unaltered histaminergic system in depression: a postmortem study. J. Affect. Disord. 146, 220\u2013223 (2013).","journal-title":"J. Affect. Disord."},{"key":"BFnrneurol201599_CR160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nrn3154","volume":"13","author":"NC Spitzer","year":"2012","unstructured":"Spitzer, N. C. Activity-dependent neurotransmitter respecification. Nat. Rev. Neurosci. 13, 94\u2013106 (2012).","journal-title":"Nat. Rev. Neurosci."},{"key":"BFnrneurol201599_CR161","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ijdevneu.2012.07.003","volume":"30","author":"DA Lee","year":"2012","unstructured":"Lee, D. A. & Blackshaw, S. Functional implications of hypothalamic neurogenesis in the adult mammalian brain. Int. J. Dev. Neurosci. 30, 615\u2013621 (2012).","journal-title":"Int. J. Dev. Neurosci."},{"key":"BFnrneurol201599_CR162","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1111\/j.1460-9568.2010.07521.x","volume":"32","author":"M Migaud","year":"2010","unstructured":"Migaud, M. et al. Emerging new sites for adult neurogenesis in the mammalian brain: a comparative study between the hypothalamus and the classical neurogenic zones. Eur. J. Neurosci. 32, 2042\u20132052 (2010).","journal-title":"Eur. J. Neurosci."},{"key":"BFnrneurol201599_CR163","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaut.2015.03.003","volume":"60","author":"M Lecendreux","year":"2015","unstructured":"Lecendreux, M. et al. Impact of cytokine in type 1 narcolepsy: role of pandemic H1N1 vaccination? J. Autoimmun. 60, 20\u201331 (2015).","journal-title":"J. Autoimmun."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2015.99.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2015.99","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2015.99.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T17:25:36Z","timestamp":1717953936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2015.99"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,23]]},"references-count":163,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["BFnrneurol201599"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2015.99","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,23]]},"assertion":[{"value":"23 June 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.D. has received funds for speaking and board engagements from Bioprojet, Jazz and UCB Pharma. L.S. and J.S. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}